Earl S Ford1, Guixiang Zhao, Chaoyang Li. 1. Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA. eford@cdc.gov <eford@cdc.gov>
Abstract
OBJECTIVES: Our objective was to estimate the magnitude of the relative risk (RR) for cardiovascular disease associated with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) from published prospective observational studies. BACKGROUND: Hyperglycemia is a known risk factor for cardiovascular disease. However, the magnitude of the RR for cardiovascular disease associated with IFG and IGT is unclear. METHODS: We searched PubMed from 1997 through 2008 for relevant publications and performed a meta-analysis. RESULTS: In 18 publications with information about IFG (110 to 125 mg/dl) (IFG 110), estimates of RR ranged from 0.65 to 2.50. The fixed-effects summary estimate of RR was 1.20 (95% confidence interval [CI]: 1.12 to 1.28). In 8 publications with information about IFG (100 to 125 mg/dl) (IFG 100), estimates of RR ranged from 0.87 to 1.40. The fixed-effects summary estimate of RR was 1.18 (95% CI: 1.09 to 1.28). In 8 publications with information about IGT, estimates of RR ranged from 0.83 to 1.34. The fixed-effects summary estimate of RR was 1.20 (95% CI: 1.07 to 1.34). Five studies combined IFG and IGT, yielding a fixed-effects summary estimate of RR of 1.10 (95% CI: 0.99 to 1.23). No significant difference between the summary estimates for men and women were detected (IFG 110: men: 1.17 [95% CI: 1.05 to 1.31], women: 1.30 [95% CI: 1.10 to 1.54]; IFG 100: men: 1.23 [95% CI: 1.06 to 1.42], women: 1.16 [95% CI: 0.99 to 1.36]). CONCLUSIONS: Impaired fasting glucose and IGT are associated with modest increases in the risk for cardiovascular disease.
OBJECTIVES: Our objective was to estimate the magnitude of the relative risk (RR) for cardiovascular disease associated with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) from published prospective observational studies. BACKGROUND:Hyperglycemia is a known risk factor for cardiovascular disease. However, the magnitude of the RR for cardiovascular disease associated with IFG and IGT is unclear. METHODS: We searched PubMed from 1997 through 2008 for relevant publications and performed a meta-analysis. RESULTS: In 18 publications with information about IFG (110 to 125 mg/dl) (IFG 110), estimates of RR ranged from 0.65 to 2.50. The fixed-effects summary estimate of RR was 1.20 (95% confidence interval [CI]: 1.12 to 1.28). In 8 publications with information about IFG (100 to 125 mg/dl) (IFG 100), estimates of RR ranged from 0.87 to 1.40. The fixed-effects summary estimate of RR was 1.18 (95% CI: 1.09 to 1.28). In 8 publications with information about IGT, estimates of RR ranged from 0.83 to 1.34. The fixed-effects summary estimate of RR was 1.20 (95% CI: 1.07 to 1.34). Five studies combined IFG and IGT, yielding a fixed-effects summary estimate of RR of 1.10 (95% CI: 0.99 to 1.23). No significant difference between the summary estimates for men and women were detected (IFG 110: men: 1.17 [95% CI: 1.05 to 1.31], women: 1.30 [95% CI: 1.10 to 1.54]; IFG 100: men: 1.23 [95% CI: 1.06 to 1.42], women: 1.16 [95% CI: 0.99 to 1.36]). CONCLUSIONS:Impaired fasting glucose and IGT are associated with modest increases in the risk for cardiovascular disease.
Authors: E E Blaak; J-M Antoine; D Benton; I Björck; L Bozzetto; F Brouns; M Diamant; L Dye; T Hulshof; J J Holst; D J Lamport; M Laville; C L Lawton; A Meheust; A Nilson; S Normand; A A Rivellese; S Theis; S S Torekov; S Vinoy Journal: Obes Rev Date: 2012-07-11 Impact factor: 9.213
Authors: Päivi Korhonen; Risto Vesalainen; Pertti Aarnio; Hannu Kautiainen; Salme Järvenpää; Ilkka Kantola Journal: Scand J Prim Health Care Date: 2012-06 Impact factor: 2.581
Authors: Revathi Balakrishnan; Jeffrey S Berger; Lisa Tully; Anish Vani; Binita Shah; Joseph Burdowski; Edward Fisher; Arthur Schwartzbard; Steven Sedlis; Howard Weintraub; James A Underberg; Ann Danoff; James A Slater; Eugenia Gianos Journal: Diabetes Metab Res Rev Date: 2015-05-12 Impact factor: 4.876
Authors: Laura N McEwen; Sara R Adams; Julie A Schmittdiel; Assiamira Ferrara; Joseph V Selby; William H Herman Journal: J Diabetes Complications Date: 2013-04-12 Impact factor: 2.852
Authors: Matthew J O'Brien; Margaret R Moran; Joyce W Tang; Maria C Vargas; Mary Talen; Laura J Zimmermann; Ronald T Ackermann; Namratha R Kandula Journal: Diabetes Educ Date: 2016-09-12 Impact factor: 2.140